We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals

438 hedge funds and large institutions have $11.7B invested in BioMarin Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 174 increasing their positions, 158 reducing their positions, and 78 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 174 | Existing positions reduced: 158

2.58% less ownership

Funds ownership: 99.51% → 96.93% (-2.6%)

9% less funds holding

Funds holding: 482 → 438 (-44)

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

27% less call options, than puts

Call options by funds: $81.3M | Put options by funds: $112M

29% less capital inflows, than outflows

Capital inflows: $844M | Capital outflows: $1.19B

58% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 78

Holders
438
Holders Change
-44
Holders Change %
-9.13%
% of All Funds
9.57%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
33
Increased
174
Reduced
158
Closed
78
Calls
$81.3​M
Puts
$112​M
Net Calls
-⁠$30.6​M
Net Calls Change
+$31.6​M

BMRN Hedge Fund Activity: Q3 2019 in Review

438 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2019, worth a combined $11.7B — down 23% from $15.3B a quarter earlier.

Sellers outnumbered buyers: 78 funds closed out of BMRN and 33 opened new positions — a net loss of 45 holders — while 158 trimmed existing stakes and 174 added.

The largest buyer was Capital Research Global Investors, adding an estimated $155M. The largest seller was Nuveen, cutting an estimated $134M.

  • 438 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2019, down from 482 in Q2 2019.
  • Funds reported $11.7B of BioMarin Pharmaceuticals stock for Q3 2019, down 23% quarter-over-quarter.
  • 33 funds opened new BioMarin Pharmaceuticals positions in Q3 2019 and 78 closed out, a net change of -45 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q3 2019 was Capital Research Global Investors, an estimated $155M added.
  • The largest BioMarin Pharmaceuticals seller in Q3 2019 was Nuveen, an estimated $134M sold.

Based on aggregated 13F filings for Q3 2019.